Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic acid-Cellulose

Aviv, H., & Leder, P. (1972) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.69.6.1408 · Cited by 6,636

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667

Direct Gene Transfer into Mouse Muscle in Vivo

Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947

Mechanisms of type-I- and type-II-interferon-mediated signalling

Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,631

Regulation of type I interferon responses

Ivashkiv, L. B., & Donlin, L. T. (2013) · Nature reviews. Immunology · doi:10.1038/nri3581 · Cited by 3,442

Interferon-stimulated genes: A complex web of host defenses

Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728

Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA

Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662

mRNA-based therapeutics--developing a new class of drugs

Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474

Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates.

Milligan, J., Groebe, D., Witherell, G. W., & Uhlenbeck, O. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.21.8783 · Cited by 1,971

Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819

Codon bias and heterologous protein expression

Gustafsson, C., Govindarajan, S., & Minshull, J. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.04.006 · Cited by 1,330

An Unstable Intermediate Carrying Information from Genes to Ribosomes for Protein Synthesis

Brenner, S., Jacob, F., & Meselson, M. S. (1961) · Nature · doi:10.1038/190576a0 · Cited by 1,235

The ins and outs of MHC class II-mediated antigen processing and presentation

Roche, P. A., & Furuta, K. (2015) · Nature reviews. Immunology · doi:10.1038/nri3818 · Cited by 1,207

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery

Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127

Surface chromium on Terracotta Army bronze weapons is neither an ancient anti-rust treatment nor the reason for their good preservation

Martinón‐Torres, M., Li, X. J., Xia, Y., Benzonelli, A., Bevan, A., Ma, S., Huang, J., Wang, L., Lan, D., Liu, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40613-7 · Cited by 1,090

Translational control by 5′-untranslated regions of eukaryotic mRNAs

Hinnebusch, A. G., Ivanov, I. P., & Sonenberg, N. (2016) · Science · doi:10.1126/science.aad9868 · Cited by 1,079

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2537-9 · Cited by 1,052

Quantitative assessment on the cloning efficiencies of lentiviral transfer vectors with a unique clone site

Zhang, G., & Tandon, A. (2012) · Scientific Reports · doi:10.1038/srep00415 · Cited by 1,039

Type I Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by Stimulating Dendritic Cells In Vivo

Bon, A. L., Schiavoni, G., D’Agostino, G., Gresser, I., Belardelli, F., & Tough, D. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00126-1 · Cited by 973

mRNA capping: biological functions and applications

Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 961

Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines

Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927

2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members

Daffis, S., Szretter, K. J., Schriewer, J. M., Li, J., Youn, S., Errett, J. S., Lin, T., Schneller, S. W., Züst, R., Dong, H., et al. (2010) · Nature · doi:10.1038/nature09489 · Cited by 910

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831

Codon optimality, bias and usage in translation and mRNA decay

Hanson, G., & Coller, J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.91 · Cited by 825

Keeping It All Going—Complement Meets Metabolism

Kolev, M. V., & Kemper, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00001 · Cited by 824

Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5

Züst, R., Cervantes-Barragan, L., Habjan, M., Maier, R., Neuman, B. W., Ziebuhr, J., Szretter, K. J., Baker, S. C., Barchet, W., Diamond, M. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.1979 · Cited by 811

A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells.

Noelle, R. J., Roy, M., Shepherd, D. M., Stamenkovic, I., Ledbetter, J. A., & Aruffo, A. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6550 · Cited by 805

Tools for translation: non-viral materials for therapeutic mRNA delivery

Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799 · cited 1×

Activation of innate immune antiviral responses by Nod2

Sabbah, A., Chang, T. H., Harnack, R., Frohlich, V. C., Tominaga, K., Dube, P. H., Xiang, Y., & Bose, S. (2009) · Nature Immunology · doi:10.1038/ni.1782 · Cited by 754

Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA

Saito, T., Owen, D. M., Jiang, F., Marcotrigiano, J., & Gale, M. (2008) · Nature · doi:10.1038/nature07106 · Cited by 737

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice

Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733

Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy

Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719

N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice

Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701

Advances in mRNA Vaccines for Infectious Diseases

Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 696

Influences of mRNA secondary structure on initiation by eukaryotic ribosomes.

Kozak, M. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.9.2850 · Cited by 687

Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation

Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682

Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant

Longhi, M. P., Trumpfheller, C., Idoyaga, J., Caskey, M. F., de Matos, I. G., Kluger, C., Salazar, A. Μ., Colonna, M., & Steinman, R. M. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090247 · Cited by 663

Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction

Zangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646

Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements

Barrett, L. W., Fletcher, S., & Wilton, S. D. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0990-9 · Cited by 641

Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to Stimulate Clonal Expansion and Differentiation

Curtsinger, J., Valenzuela, J. O., Agarwal, P., Lins, D. C., & Mescher, M. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4465 · Cited by 633

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells

Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625

Vitamin D Is Required for ILC3 Derived IL-22 and Protection From Citrobacter rodentium Infection

Lin, Y., Arora, J., Diehl, K. C., Bora, S. A., & Cantorna, M. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00001 · Cited by 602

A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA

Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569

COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.

Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021) · PubMed · doi:10.26355/eurrev_202102_24877 · Cited by 564

G-quadruplexes: a promising target for cancer therapy

Kosiol, N., Juranek, S., Brossart, P., Heine, A., & Paeschke, K. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01328-4 · Cited by 561

mRNA structure regulates protein expression through changes in functional half-life

Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555

Complex modulation of cell type-specific signaling in response to type I interferons

van Boxel-Dezaire, A. H. H., Rani, M. R. S., & Stark, G. R. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.014 · Cited by 530

A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis

Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., Akilli-Öztürk, Ö., Kranz, L. M., Berger, H., Petschenka, J., et al. (2021) · Science · doi:10.1126/science.aay3638 · Cited by 520

Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals

Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513 · cited 5×

Recent advances in mRNA vaccine technology

Pardi, N., Hogan, M. J., & Weissman, D. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.008 · Cited by 512

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases

Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507

The dawn of mRNA vaccines: the COVID-19 case

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504

Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses

Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501

Regulation of antiviral T cell responses by type I interferons

Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature reviews. Immunology · doi:10.1038/nri3806 · Cited by 493

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species soecificity

Symons, J. A., Alcamı́, A., & Smith, G. L. (1995) · Cell · doi:10.1016/0092-8674(95)90076-4 · Cited by 491

Self-amplifying RNA vaccines for infectious diseases

Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487

High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells

Kudla, G., Lipinski, L., Caffin, F., Helwak, A., & Zylicz, M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040180 · Cited by 476

Role of 5′‐ and 3′‐untranslated regions of mRNAs in human diseases

Chatterjee, S., & Pal, J. K. (2009) · Biology of the Cell · doi:10.1042/bc20080104 · Cited by 439

Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination

Tam, H. H., Melo, M. B., Kang, M., Pelet, J. M., Ruda, V. M., Foley, M. H., Hu, J. K., Kumari, S., Crampton, J., Baldeon, A. D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606050113 · Cited by 425

The challenge and prospect of mRNA therapeutics landscape

Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417

Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics

Leppek, K., Byeon, G. W., Kladwang, W., Wayment-Steele, H. K., Kerr, C. H., Xu, A. F., Kim, D. S., Topkar, V. V., Choe, C., Rothschild, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28776-w · Cited by 399

Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics

Leppek, K., Byeon, G. W., Kladwang, W., Wayment-Steele, H. K., Kerr, C. H., Xu, A. F., Kim, D. S., Topkar, V. V., Choe, C., Rothschild, D., et al. (2021) · doi:10.1101/2021.03.29.437587 · Cited by 399

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Lederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.009 · Cited by 383 · cited 1×

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening

Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365

Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity

Smith, G. L., Benfield, C. T. O., de Motes, C. M., Mazzon, M., Ember, S. W., Ferguson, B. J., & Sumner, R. P. (2013) · Journal of General Virology · doi:10.1099/vir.0.055921-0 · Cited by 364

Structural basis for m7G recognition and 2′-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I

Devarkar, S. C., Wang, C., Miller, M. T., Ramanathan, A., Jiang, F., Khan, A. G., Patel, S. S., & Marcotrigiano, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515152113 · Cited by 357

Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L

Anderson, B. R., Muramatsu, H., Jha, B. K., Silverman, R. H., Weissman, D., & Kariko, K. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr586 · Cited by 356

A Role for Codon Order in Translation Dynamics

Cannarozzi, G., Schraudolph, N. N., Faty, M., von Rohr, P., Friberg, M. T., Roth, A. C., Gonnet, P., Gonnet, G., & Barral, Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.036 · Cited by 354

Impact of mRNA chemistry and manufacturing process on innate immune activation

Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354

Activation of Innate Immunity Is Required for Efficient Nuclear Reprogramming

Lee, J., Sayed, N., Hunter, A. L., Au, K. F., Wong, W. H., Mocarski, E. S., Pera, R. A. R., Yakubov, E., & Cooke, J. P. (2012) · Cell · doi:10.1016/j.cell.2012.09.034 · Cited by 345

A critical analysis of codon optimization in human therapeutics

Mauro, V. P., & Chappell, S. A. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.09.003 · Cited by 343

Untitled work

(2001) · PubMed Central · Cited by 342

Three decades of messenger RNA vaccine development

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342

A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines

Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., & Neyns, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4121 · Cited by 316

Efficient generation of human iPSCs by a synthetic self-replicative RNA

Yoshioka, N., Gros, E., Li, H.-R., Kumar, S., Deacon, D. C., Maron, C., Muotri, A. R., Chi, N. C., Fu, X.-D., Yu, B. D., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.06.001 · Cited by 312

A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1-2′O-Methylated Self RNA

Schuberth-Wagner, C., Ludwig, J., Bruder, A. K., Herzner, A., Zillinger, T., Goldeck, M., Schmidt, T., Schmid-Burgk, J. L., Kerber, R., Wolter, S., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.015 · Cited by 311

Short poly(A) tails are a conserved feature of highly expressed genes

Lima, S. A., Chipman, L. B., Nicholson, A. L., Chen, Y.-H., Yee, B. A., Yeo, G. W.-M., Coller, J., & Pasquinelli, A. E. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3499 · Cited by 292

An Update on Self-Amplifying mRNA Vaccine Development

Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288

Alphavirus RNA synthesis and non-structural protein functions

Rupp, J. C., Sokoloski, K. J., Gebhart, N. N., & Hardy, R. W. (2015) · Journal of General Virology · doi:10.1099/jgv.0.000249 · Cited by 285

Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin

Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282

Nucleic acid agonists for Toll‐like receptor 7 are defined by the presence of uridine ribonucleotides

Diebold, S. S., Massacrier, C., Akira, S., Paturel, C., Morel, Y., & Sousa, C. R. E. (2006) · European Journal of Immunology · doi:10.1002/eji.200636617 · Cited by 281

Control of poly(A) tail length

Eckmann, C. R., Rammelt, C., & Wahle, E. (2010) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.56 · Cited by 277

The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms

Davies, M. V., Chang, H. W., Jacobs, B. L., & Kaufman, R. J. (1993) · Journal of Virology · doi:10.1128/jvi.67.3.1688-1692.1993 · Cited by 274

The Vaccinia Virus Soluble Alpha/Beta Interferon (IFN) Receptor Binds to the Cell Surface and Protects Cells from the Antiviral Effects of IFN

Alcamı́, A., Symons, J. A., & Smith, G. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11230-11239.2000 · Cited by 274

IFN‐α/β enhances BCR‐dependent B cell responses

Braun, D., Caramalho, Í., & Demengeot, J. (2002) · International Immunology · doi:10.1093/intimm/14.4.411 · Cited by 269

Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1

de Weerd, N. A., Vivian, J. P., Nguyen, T. K., Mangan, N. E., Gould, J. A., Braniff, S.-J., Zaker-Tabrizi, L., Fung, K. Y., Forster, S. C., Beddoe, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2667 · Cited by 267

Processivity in early stages of transcription by T7 RNA polymerase

Martin, C. T., Muller, D. K., & Coleman, J. E. (1988) · Biochemistry · doi:10.1021/bi00411a012 · Cited by 264

Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification

Vaidyanathan, S., Azizian, K. T., Haque, A. K. M. A., Henderson, J. M., Hendel, A., Shore, S., Antony, J. S., Hogrefe, R. I., Kormann, M. S. D., Porteus, M. H., et al. (2018) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2018.06.010 · Cited by 262 · cited 1×

Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA

Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., Rammensee, H.-G., Garbe, C., & Pascolo, S. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815ce501 · Cited by 261 · cited 1×

Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling

Zhang, H., You, X., Wang, X., Cui, L., Wang, Z., Xu, F., Li, M., Yang, Z., Liu, J., Huang, P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005191118 · Cited by 252

The Influenza Virus Protein PB1-F2 Inhibits the Induction of Type I Interferon at the Level of the MAVS Adaptor Protein

Varga, Z. T., Ramos, I., Hai, R., Schmolke, M., García‐Sastre, A., Fernández-Sesma, A., & Palese, P. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002067 · Cited by 246

Small molecule ISRIB suppresses the integrated stress response within a defined window of activation

Rabouw, H. H., Langereis, M. A., Anand, A. A., Visser, L. J., de Groot, R. J., Walter, P., & van Kuppeveld, F. J. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815767116 · Cited by 242

Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus

Honke, N., Shaabani, N., Cadeddu, G., Sorg, U. R., Zhang, D., Trilling, M., Klingel, K., Sauter, M., Kandolf, R., Gailus, N., et al. (2011) · Nature Immunology · doi:10.1038/ni.2169 · Cited by 241

The molecular basis for differential type I interferon signaling

Schreiber, G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.774562 · Cited by 240

PKR Stimulates NF-κB Irrespective of Its Kinase Function by Interacting with the IκB Kinase Complex

Bonnet, M., Weil, R., Dam, E., Hovanessian, A. G., & MEURS, E. F. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.13.4532-4542.2000 · Cited by 234

Mechanism of action of mRNA-based vaccines

Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234

Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives

Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., Solinís, M. Á., & del Pozo‐Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 229

RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?

Meng, Z., & Lu, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00331 · Cited by 226

ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity

Lamers, M. M., van den Hoogen, B. G., & Haagmans, B. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01763 · Cited by 224

A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines

Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25181 · Cited by 223

Reprogramming human fibroblasts to pluripotency using modified mRNA

Mandal, P., & Rossi, D. J. (2013) · Nature Protocols · doi:10.1038/nprot.2013.019 · Cited by 219

Naturally occurring modified ribonucleosides

McCown, P. J., Ruszkowska, A., Kunkler, C. N., Breger, K., Hulewicz, J. P., Wang, M. C., Springer, N. A., & Brown, J. A. (2020) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1595 · Cited by 219

An origin of the immunogenicity of in vitro transcribed RNA

Mu, X., Greenwald, E., Ahmad, S., & Hur, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky177 · Cited by 218

The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2

Davies, M. V., Elroy‐Stein, O., Jagus, R., Moss, B., & Kaufman, R. J. (1992) · Journal of Virology · doi:10.1128/jvi.66.4.1943-1950.1992 · Cited by 214

A trans-amplifying RNA vaccine strategy for induction of potent protective immunity

Beissert, T., Perkovic, M., Vogel, A., Erbar, S., Walzer, K. C., Hempel, T., Brill, S., Haefner, E., Becker, R., Türeci, Ö., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.009 · Cited by 212

Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design

Pepini, T., Pulichino, A.-M., Carsillo, T., Carlson, A. L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J. C., Maruggi, G., Otten, G. R., Geall, A. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601877 · Cited by 208

Self-coded 3′-Extension of Run-off Transcripts Produces Aberrant Products during in Vitro Transcription with T7 RNA Polymerase

Triana‐Alonso, F. J., Dabrowski, M., Wadzack, J., & Nierhaus, K. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.11.6298 · Cited by 207

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

Probst, J., Weide, B., Scheel, B., Pichler, B. J., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302964 · Cited by 206

In Vitro Transcription of Long RNA Containing Modified Nucleosides

Pardi, N., Muramatsu, H., Weissman, D., & Karikó, K. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_2 · Cited by 204

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

Wilgenhof, S., Nuffel, A. M. T. V., Benteyn, D., Corthals, J., Aerts, C., Heirman, C., Riet, I. V., Bonehill, A., Thielemans, K., & Neyns, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt245 · Cited by 204

A periodic pattern of mRNA secondary structure created by the genetic code

Shabalina, S. A. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl287 · Cited by 202

Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo

Kauffman, K. J., Mir, F. F., Jhunjhunwala, S., Kaczmarek, J. C., Hurtado, J. E., Yang, J. H., Webber, M. J., Kowalski, P. S., Heartlein, M. W., DeRosa, F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.006 · Cited by 195

RNA: The new revolution in nucleic acid vaccines

Geall, A. J., Mandl, C. W., & Ulmer, J. B. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.05.001 · Cited by 193

Functions of the influenza A virus NS1 protein in antiviral defense

Krug, R. M. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.01.007 · Cited by 188

Selection of RNA Replicons Capable of Persistent Noncytopathic Replication in Mammalian Cells

Frolov, I. V., Agapov, E. V., Hoffman, T. A., Prágai, B. M., Lippa, M., Schlesinger, S., & Rice, C. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3854-3865.1999 · Cited by 186

mRNA-based dendritic cell vaccines

Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K., & Breckpot, K. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.957684 · Cited by 186

Clinical and immunological effects of mRNA vaccines in malignant diseases

Heine, A., Juranek, S., & Brossart, P. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01339-1 · Cited by 186

3′ end additions by T7 RNA polymerase are RNA self-templated, distributive and diverse in character—RNA-Seq analyses

Gholamalipour, Y., Mudiyanselage, A. K., & Martin, C. T. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky796 · Cited by 182

Self-Amplifying mRNA Vaccines

Brito, L. A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Scorza, F. B., Otten, G. R., Yu, D. L., Mandl, C. W., Mason, P. W., et al. (2014) · Advances in genetics · doi:10.1016/bs.adgen.2014.10.005 · Cited by 181

Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines

Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A., & Geall, A. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.901308 · Cited by 180

The Interferon System and Vaccinia Virus Evasion Mechanisms

Perdiguero, B., & Estéban, M. (2009) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2009.0073 · Cited by 178

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma

Keersmaecker, B. D., Claerhout, S., Carrasco, J., Bar, I., Corthals, J., Wilgenhof, S., Neyns, B., & Thielemans, K. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000329 · Cited by 176

mRNA transfection of dendritic cells: Synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level

Mockey, M., Gonçalves, C., Dupuy, F. P., Lemoine, F. M., Pichon, C., & Midoux, P. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.105 · Cited by 165

Alphavirus polymerase and RNA replication

Pietilä, M. K., Hellström, K., & Ahola, T. (2017) · Virus Research · doi:10.1016/j.virusres.2017.01.007 · Cited by 163

A Single N66S Mutation in the PB1-F2 Protein of Influenza A Virus Increases Virulence by Inhibiting the Early Interferon Response In Vivo

Conenello, G. M., Tisoncik-Go, J., Rosenzweig, E., Varga, Z. T., Palese, P., & Katze, M. G. (2010) · Journal of Virology · doi:10.1128/jvi.01987-10 · Cited by 162

Alphavirus Infection: Host Cell Shut-Off and Inhibition of Antiviral Responses

Fros, J. J., & Pijlman, G. P. (2016) · Viruses · doi:10.3390/v8060166 · Cited by 158

A sharp T-cell antigen receptor signaling threshold for T-cell proliferation

Au‐Yeung, B. B., Zikherman, J., Mueller, J. L., Ashouri, J. F., Matloubian, M., Cheng, D. A., Chen, Y., Shokat, K. M., & Weiss, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413726111 · Cited by 156

Determinants and implications of mRNA poly(A) tail size – Does this protein make my tail look big?

Jalkanen, A. L., Coleman, S. J., & Wilusz, J. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.05.018 · Cited by 154

Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA

Warren, L., Ni, Y., Wang, J., & Guo, X. (2012) · Scientific Reports · doi:10.1038/srep00657 · Cited by 154

Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans

Cagigi, A., & Loré, K. (2021) · Vaccines · doi:10.3390/vaccines9010061 · Cited by 153

Messenger RNA-based vaccines

Pascolo, S. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.8.1285 · Cited by 152

B‐cell activation by membrane‐bound antigens is facilitated by the interaction of VLA‐4 with VCAM‐1

Carrasco, Y. R., & Batista, F. D. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600944 · Cited by 150

Noncytopathic Replication of Venezuelan Equine Encephalitis Virus and Eastern Equine Encephalitis Virus Replicons in Mammalian Cells

Petrakova, O., Volkova, E., Gorchakov, R., Paessler, S., Kinney, R., & Frolov, I. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7597-7608.2005 · Cited by 148

Rapid, nondenaturing RNA purification using weak anion-exchange fast performance liquid chromatography

Easton, L. E., Shibata, Y., & Lukavsky, P. J. (2010) · RNA · doi:10.1261/rna.1862210 · Cited by 143

Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner

Nallagatla, S. R., & Bevilacqua, P. C. (2008) · RNA · doi:10.1261/rna.1007408 · Cited by 143

Antigen Availability Determines CD8+ T Cell-Dendritic Cell Interaction Kinetics and Memory Fate Decisions

Henrickson, S. E., Perro, M., Loughhead, S. M., Senman, B. C., Stutte, S., Quigley, M. M., Alexe, G., Iannacone, M., Flynn, M. P., Omid, S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.034 · Cited by 142

In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency

Mahiny, A. J., Dewerth, A., Mays, L. E., Alkhaled, M., Mothes, B., Malaeksefat, E., Loretz, B., Rottenberger, J., Brosch, D. M., Reautschnig, P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3241 · Cited by 139 · cited 1×

Challenges and advances towards the rational design of mRNA vaccines

Pollard, C., Koker, S. D., Saelens, X., Vanham, G. L., & Grooten, J. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.09.002 · Cited by 138

Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response

Foster, J., Choudhari, N., Perazzelli, J., Storm, J., Hofmann, T. J., Jain, P., Storm, P. B., Pardi, N., Weissman, D., Waanders, A. J., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.145 · Cited by 138

Activation of NF-κB by the dsRNA-dependent protein kinase, PKR involves the IκB kinase complex

Gil, J., Alcamı́, J., & Estéban, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203448 · Cited by 137

Synthesis of low immunogenicity RNA with high-temperature in vitro transcription

Wu, M. Z., Asahara, H., Tzertzinis, G., & Roy, B. (2020) · RNA · doi:10.1261/rna.073858.119 · Cited by 135

Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA

Verbeke, R., Lentacker, I., Wayteck, L., Breckpot, K., Van Bockstal, M., Descamps, B., Vanhove, C., De Smedt, S. C., & Dewitte, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.041 · Cited by 132

Inhibition of the OAS/RNase L pathway by viruses

Drappier, M., & Michiels, T. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.07.002 · Cited by 129

Codon Optimization in the Production of Recombinant Biotherapeutics: Potential Risks and Considerations

Mauro, V. P. (2018) · BioDrugs · doi:10.1007/s40259-018-0261-x · Cited by 129

mRNA therapeutics deliver a hopeful message

Zhong, Z., Cafferty, S. M., Combes, F., Huysmans, H., Temmerman, J. D., Gitsels, A., Vanrompay, D. C. G., Catani, J. P., & Sanders, N. N. (2018) · Nano Today · doi:10.1016/j.nantod.2018.10.005 · Cited by 124

Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses

De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V. K., Smet, M., Sanders, N., Lienenklaus, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.161 · Cited by 122

Replicon Vectors Derived from Sindbis Virus and Semliki Forest Virus That Establish Persistent Replication in Host Cells

Perri, S., Driver, D. A., Gardner, J. P., Sherrill, S., Belli, B., Dubensky, T. W., & Polo, J. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9802-9807.2000 · Cited by 121

Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon

Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.38 · Cited by 121

Fine-Tuning of Type I Interferon Response by STAT3

Tsai, M.-H., Pai, L., & Lee, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01448 · Cited by 117

Cutting Edge: Innate Immune System Discriminates between RNA Containing Bacterial versus Eukaryotic Structural Features That Prime for High-Level IL-12 Secretion by Dendritic Cells

Koski, G. K., Karikó, K., Xu, S., Weissman, D., Cohen, P. A., & Czerniecki, B. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.3989 · Cited by 116

Identification of Mutations in a Sindbis Virus Variant Able to Establish Persistent Infection in BHK Cells: The Importance of a Mutation in the nsP2 Gene

Dryga, S. A., DRYGA, O. A., & Schlesinger, S. (1997) · Virology · doi:10.1006/viro.1996.8364 · Cited by 116

mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response

Tse, S., McKinney, K. M., Walker, W., Nguyen, M., Iacovelli, J., Small, C. G., Hopson, K., Zaks, T. Z., & Huang, E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.002 · Cited by 114

Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger.

Devoldere, J., Dewitte, H., De Smedt, S. C., & Remaut, K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.009 · Cited by 112

Synthetic mRNA capping

Muttach, F., Muthmann, N., & Rentmeister, A. (2017) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.13.274 · Cited by 112

mRNA: Fulfilling the Promise of Gene Therapy

Weissman, D., & Karikó, K. (2015) · Molecular Therapy · doi:10.1038/mt.2015.138 · Cited by 111

Influenza A Virus Protein PB1-F2 Exacerbates IFN-β Expression of Human Respiratory Epithelial Cells

Goffic, R. L., Bouguyon, E., Chevalier, C., Vidić, J., da Costa, B. R., Leymarie, O., Bourdieu, C., Decamps, L., Dhorne‐Pollet, S., & Delmas, B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903952 · Cited by 111

Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines

Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 110

Rapid purification of RNAs using fast performance liquid chromatography (FPLC)

Kim, I., McKenna, S. A., Puglisi, E. V., & Puglisi, J. D. (2006) · RNA · doi:10.1261/rna.342607 · Cited by 106

Influenza A virus-encoded NS1 virulence factor protein inhibits innate immune response by targeting IKK

Gao, S., Song, L., Li, J., Zhang, Z., Peng, H., Jiang, W., Wang, Q., Kang, T., Chen, S., & Huang, W. (2012) · Cellular Microbiology · doi:10.1111/cmi.12005 · Cited by 105

Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant

Pons-Faudoa, F. P., Trani, N. D., Sizovs, A., Shelton, K. A., Momin, Z. K., Bushman, L. R., Xu, J., Lewis, D. E., Demaria, S., Hawkins, T., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100981 · Cited by 105

Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA

Blakney, A. K., McKay, P. F., Bouton, C. R., Hu, K., Samnuan, K., & Shattock, R. J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.011 · Cited by 105

Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes

Ross, J., & Sullivan, T. (1985) · Blood · doi:10.1182/blood.v66.5.1149.1149 · Cited by 104

ADARs: Viruses and Innate Immunity

Samuel, C. E. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_148 · Cited by 103

Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection

Leal, L., Guardo, A. C., Morón‐López, S., Salgado, M., Mothe, B., Heirman, C., Pannus, P., Vanham, G., van den Ham, H., Gruters, R. A., et al. (2018) · AIDS · doi:10.1097/qad.0000000000002026 · Cited by 102

RNA Recognition via TLR7 and TLR8

Hornung, V., Barchet, W., Schlee, M., & Hartmann, G. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-72167-3_4 · Cited by 99

Self-Amplifying RNA Viruses as RNA Vaccines

Lundstrom, K. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145130 · Cited by 99

Purification and characterization of transcribed RNAs using gel filtration chromatography

McKenna, S. A., Kim, I., Puglisi, E. V., Lindhout, D. A., Aitken, C. E., Marshall, R. A., & Puglisi, J. D. (2007) · Nature Protocols · doi:10.1038/nprot.2007.480 · Cited by 98

Regulation of α-Globin mRNA Stability

Waggoner, S. A., & Liebhaber, S. A. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800409 · Cited by 98

Bacterial RNA: An Underestimated Stimulus for Innate Immune Responses

Eigenbrod, T., & Dalpke, A. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500530 · Cited by 96

pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences

Grier, A. E., Burleigh, S., Sahni, J., Clough, C. A., Cardot, V., Choe, D. C., Krutein, M. C., Rawlings, D. J., Jensen, M. C., Scharenberg, A. M., et al. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.21 · Cited by 95

Innate Immune Suppression Enables Frequent Transfection with RNA Encoding Reprogramming Proteins

Angel, M., & Yanik, M. F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011756 · Cited by 91

The influenza virus PB1-F2 protein has interferon antagonistic activity

Dudek, S. E., Wixler, L., Nordhoff, C., Nordmann, A., Anhlan, D., Wixler, V., & Ludwig, S. (2011) · Biological Chemistry · doi:10.1515/bc.2011.174 · Cited by 89

Overexpression of urokinase receptor in mammalian cells following administration of the in vitro transcribed encoding mRNA

Karikó, K., Kuo, A., & Barnathan, E. S. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300930 · Cited by 89

Viral RNA recognition by LGP2 and MDA5, and activation of signaling through step-by-step conformational changes

Duic, I., Tadakuma, H., Harada, Y., Yamaue, R., Deguchi, K., Suzuki, Y., Yoshimura, S. H., Kato, H., Takeyasu, K., & Fujita, T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa935 · Cited by 86

Replication of RNA by the DNA-dependent RNA polymerase of phage T7

Konarska, M. M., & Sharp, P. A. (1989) · Cell · doi:10.1016/0092-8674(89)90917-3 · Cited by 85

Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells

Verbeke, R., Lentacker, I., Breckpot, K., Janssens, J., Calenbergh, S. V., Smedt, S. C. D., & Dewitte, H. (2019) · ACS Nano · doi:10.1021/acsnano.8b07660 · Cited by 85

A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice

Roth, C., Cantaert, T., Colas, C., Prot, M., Casadémont, I., Levillayer, L., Thalmensi, J., Langlade‐Demoyen, P., Gerke, C., Bahl, K., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01424 · Cited by 84

LGP2 binds to PACT to regulate RIG-I– and MDA5-mediated antiviral responses

Sanchez-David, R. Y., Combredet, C., Najburg, V., Millot, G. A., Beauclair, G., Schwikowski, B., Léger, T., Camadro, J., Jacob, Y., Bellalou, J., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aar3993 · Cited by 82

The Activation Mechanism of 2′-5′-Oligoadenylate Synthetase Gives New Insights Into OAS/cGAS Triggers of Innate Immunity

Lohoefener, J., Steinke, N., Kay-Fedorov, P. C., Baruch, P., Никулин, А. Д., Tishchenko, S., Manstein, D. J., & Fedorov, R. (2015) · Structure · doi:10.1016/j.str.2015.03.012 · Cited by 81

Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins

Beißert, T., Koste, L., Perković, M., Walzer, K. C., Erbar, S., Selmi, A., Diken, M., Kreiter, S., Türeci, Ö., & Şahin, U. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.121 · Cited by 81

Sustained Vaccination Coverage during the Coronavirus Disease 2019 Epidemic in the Republic of Korea

Yu, J. H., Jeong, H. J., Kim, S. J., Lee, J. Y., Choe, Y. J., Choi, E. H., & Cho, E. H. (2020) · Vaccines · doi:10.3390/vaccines9010002 · Cited by 81

The 3′ Untranslated Region of Sindbis Virus Represses Deadenylation of Viral Transcripts in Mosquito and Mammalian Cells

Garneau, N. L., Sokoloski, K. J., Opyrchal, M., Neff, C. P., Wilusz, C. J., & Wilusz, J. (2007) · Journal of Virology · doi:10.1128/jvi.01205-07 · Cited by 80

Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines

Alfagih, I. M., Aldosari, B. N., AlQuadeib, B. T., Almurshedi, A. S., & Alfagih, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010045 · Cited by 80

Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update

Dörrie, J., Schaft, N., Schuler, G., & Schuler‐Thurner, B. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020092 · Cited by 79

Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion

Poleganov, M. A., Eminli, S., Beissert, T., Herz, S., Moon, J.-I., Goldmann, J., Beyer, A., Heck, R., Burkhart, I., Barea Roldan, D., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.045 · Cited by 77

mRNA-based therapeutics–Advances and perspectives

Sergeeva, O. V., Koteliansky, V., & Zatsepin, T. S. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916070075 · Cited by 74

mRNA as a Versatile Tool for Exogenous Protein Expression

Kuhn, A. N., Beißert, T., Simon, P., Vallazza, B., Buck, J., Davies, B. P., Türeci, Ö., & Şahin, U. (2012) · Current Gene Therapy · doi:10.2174/156652312802762536 · Cited by 73

Molecular Insights into Reprogramming-Initiation Events Mediated by the OSKM Gene Regulatory Network

Mah, N., Wang, Y., Liao, M.-C., Prigione, A., Józefczuk, J., Lichtner, B., Wolfrum, K., Haltmeier, M., Flöttmann, M., Schaefer, M. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024351 · Cited by 72

Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment

Dewitte, H., Verbeke, R., Breckpot, K., Smedt, S. C. D., & Lentacker, I. (2014) · Nano Today · doi:10.1016/j.nantod.2014.10.001 · Cited by 71

In vitro evolution of enhanced RNA replicons for immunotherapy

Li, Y., Teague, B., Zhang, Y., Su, Z., Porter, E., Dobosh, B., Wagner, T., Irvine, D. J., & Weiss, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-43422-0 · Cited by 71

Messenger RNA (mRNA) nanoparticle tumour vaccination

Phua, K. K. L., Nair, S. K., & Leong, K. W. (2014) · Nanoscale · doi:10.1039/c4nr01346h · Cited by 70

Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration

Devoldere, J., Peynshaert, K., Dewitte, H., Vanhove, C., Groef, L. D., Moons, L., Özcan, S. Y., Dalkara, D., Smedt, S. C. D., & Remaut, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.042 · Cited by 70

mRNA-based therapeutics: powerful and versatile tools to combat diseases

Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

Shi, Y., Shi, M., Wáng, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 243

Chemically Modified Platforms for Better RNA Therapeutics

Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 189

Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines

Kim, B., Hosn, R. R., Remba, T. K., Yun, D. S., Li, N., Abraham, W. D., Melo, M. B., Cortés, M., Li, B., Zhang, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.022 · Cited by 157

mRNA in the Context of Protein Replacement Therapy

Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 145

Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development

Schmidt, C., & Schnierle, B. S. (2023) · Pathogens · doi:10.3390/pathogens12010138 · Cited by 78

The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics

Muslimov, A. R., Tereshchenko, V., Shevyrev, D., Rogova, A. S., Lepik, K. V., Reshetnikov, V. V., & Ivanov, R. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914820 · Cited by 51

Self-amplifying mRNA vaccines: Mode of action, design, development and optimization

Pourseif, M. M., Masoudi‐Sobhanzadeh, Y., Azari, E., Parvizpour, S., Barar, J., Ansari, R. A., & Omidi, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103341 · Cited by 57

Self-amplifying RNA—opportunities and challenges

Groppo, R. (2024) · Nucleic Acid Insights · doi:10.18609/nai.2024.025 · Cited by 1

Self-replicating RNA for mRNA vaccine development

Lundstrom, K. H. (2024) · Cell and Gene Therapy Insights · doi:10.18609/cgti.2024.074